YMAB insider transactions
Y-mAbs Therapeutics Inc. (YMAB) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
YMAB insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Y-mAbs Therapeutics Inc., latest first. Follow anyone to get their next filing.
- Laura HamillDirector
- Biotech ApS WgDirector, 10% owner+$2.75M-$6.96M
- Douglas J GentilcoreSVP, Danyelza Bus. Unit Head, since January 2025
- David N GillDirector-$93K
- Ashu TyagiDirector
- Thomas GadChief Business Officer, Director-$21.3M
- Peter P. PfreundschuhEVP, CFO and Treasurer, since June 2024
- Michael J RossiPresident & CEO, Director, since November 2023-$20.4K
- Joris WilmsSVP & Chief Operating Officer-$73.5K
- Johan Wedell-WedellsborgDirector, 10% owner+$2.75M-$8.28M
- John LaRoccaSVP, General Counsel & Secry, since January 2025
- James HealyDirector
- Torben Lund-HansenSVP & Chief Technical Officer-$769K
- Mary TagliaferriDirector, since February 2024
- Gerard BerDirector-$8,664
- Bo KruseEVP, CFO, Secry & Treas.-$2.62M
- Vignesh RajahSVP & Chief Medical Officer+$47K-$28.3K
- Susan Laura SmithSVP & Chief Commercial Officer, since December 2021-$27.8K
- Steen LisbySVP & Chief Scientific Officer
- Moller-San Pedro Claus JuanOfficer, Director
Recent Form 3, 4, and 5 filings for YMAB
- Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Gill David N returned $50,095 worth of shares to the company (30,905 units at $1.62), closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Tyagi Ashu returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CHIEF BUSINESS OFFICER Gad Thomas returned 60,235 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- EVP, CFO and Treasurer Pfreundschuh Peter P. returned 77,800 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- PRESIDENT & CEO Rossi Michael J returned 129,101 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SVP & CHIEF OPERATING OFFICER Wilms Joris returned 39,301 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Wedell-Wedellsborg Johan returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SVP, General Counsel & Secry Larocca John returned 21,500 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Healy James returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Tyagi Ashu was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Hamill Laura was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Healy James was granted 25,080 shares, increasing direct ownership by 79% to 56,683 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Wedell-Wedellsborg Johan was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Gill David N was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CHIEF BUSINESS OFFICER Gad Thomas exercised 103,000 shares at a strike of $2.00, increasing direct ownership by 51% to 305,721 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- PRESIDENT & CEO Rossi Michael J sold $20,368 worth of shares (3,917 units at $5.20), decreasing direct ownership by 3% to 137,083 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CHIEF BUSINESS OFFICER Gad Thomas sold $56,536 worth of shares (10,810 units at $5.23), decreasing direct ownership by 5% to 202,721 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CFO and Treasurer Pfreundschuh Peter P. was granted 31,800 shares, increasing direct ownership by 69% to 77,800 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CHIEF BUSINESS OFFICER Gad Thomas was granted 32,000 shares, increasing direct ownership by 18% to 213,531 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SVP & CHIEF OPERATING OFFICER Wilms Joris was granted 21,500 shares, increasing direct ownership by 70% to 52,100 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- PRESIDENT & CEO Rossi Michael J was granted 105,300 shares, increasing direct ownership by 295% to 141,000 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SVP, General Counsel & Secry Larocca John was granted 21,500 shares (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SEC Form 3 filed by new insider Gentilcore Douglas J3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SEC Form 3 filed by new insider Larocca John3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CHIEF BUSINESS OFFICER Gad Thomas exercised 22,831 shares at a strike of $4.38, increasing direct ownership by 14% to 181,531 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CHIEF BUSINESS OFFICER Gad Thomas sold $1,264,650 worth of shares (95,000 units at $13.31) (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SVP & CHIEF TECHNICAL OFFICER Lund-Hansen Torben exercised 50,000 shares at a strike of $4.38 and sold $768,500 worth of shares (50,000 units at $15.37) (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SVP & CHIEF OPERATING OFFICER Wilms Joris sold $73,450 worth of shares (5,000 units at $14.69), decreasing direct ownership by 14% to 30,600 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CFO and Treasurer Pfreundschuh Peter P. was granted 46,000 shares (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SEC Form 3 filed by new insider Pfreundschuh Peter P.3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Tagliaferri Mary was granted 3,495 shares, increasing direct ownership by 75% to 8,155 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Hamill Laura was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Wedell-Wedellsborg Johan was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Healy James was granted 3,495 shares, increasing direct ownership by 12% to 31,603 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Gill David N was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Tyagi Ashu was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Director Ber Gerard sold $8,664 worth of shares (722 units at $12.00), decreasing direct ownership by 31% to 1,608 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- CHIEF BUSINESS OFFICER Gad Thomas sold $841,050 worth of shares (70,000 units at $12.02) (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Kruse Bo sold $723,055 worth of shares (60,000 units at $12.05) and exercised 60,000 shares at a strike of $2.00 (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Gad Thomas sold $395,563 worth of shares (32,351 units at $12.23) (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Tagliaferri Mary was granted 4,660 shares (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- SEC Form 3 filed by new insider Tagliaferri Mary3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Rajah Vignesh sold $28,283 worth of shares (1,711 units at $16.53), decreasing direct ownership by 5% to 33,889 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Gad Thomas sold $64,116 worth of shares (3,900 units at $16.44), decreasing direct ownership by 2% to 158,700 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Smith Susan Laura sold $27,837 worth of shares (1,682 units at $16.55), decreasing direct ownership by 5% to 33,918 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Rossi Michael J was granted 35,700 shares (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Rajah Vignesh was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Smith Susan Laura was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Lisby Steen was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Wilms Joris was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Lund-Hansen Torben was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Gad Thomas was granted 22,100 shares, increasing direct ownership by 16% to 162,600 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Kruse Bo was granted 18,100 shares, increasing direct ownership by 9% to 210,877 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Gad Thomas exercised 50,000 shares at a strike of $2.00, increasing direct ownership by 55% to 140,500 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Gad Thomas sold $1,001,000 worth of shares (150,000 units at $6.67) (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
- Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)